GENENTECH, INC.
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
- Conditions
- Interventions
- First Posted Date
- 2011-08-11
- Last Posted Date
- 2018-04-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT01414855
- Locations
- πΊπΈ
Norwalk Hospital, Norwalk, Connecticut, United States
πΊπΈOnc Hem Assoc of Central IL, Peoria, Illinois, United States
πΊπΈFlorida Cancer Specialists; Saint Petersburg, Saint Petersburg, Florida, United States
A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-07-22
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 127
- Registration Number
- NCT01399684
A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT01397578
- Locations
- πͺπΈ
Hospital Mutua De Terrasa, Barcelona, Spain
πΊπΈNNS Clinical Research LLC, Tucson, Arizona, United States
πΊπΈPacific Neuroscience Med Grp, Oxnard, California, United States
A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 661
- Registration Number
- NCT01375842
- Locations
- πΊπΈ
The Angeles Clinic, Los Angeles, California, United States
πΊπΈUni of Chicago, Chicago, Illinois, United States
πΊπΈNew York Oncology Hematology, P.C., Albany, New York, United States
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)
- Conditions
- Interventions
- First Posted Date
- 2011-06-16
- Last Posted Date
- 2016-08-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 376
- Registration Number
- NCT01374425
Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)
- Conditions
- Interventions
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT01366131
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 555
- Registration Number
- NCT01366209
- Locations
- πΊπΈ
InterMune Inc., Brisbane, California, United States
Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT01363947
- Locations
- πΊπΈ
HonorHealth Research Institute - Pima Center, Scottsdale, Arizona, United States
πͺπΈHospital del Mar; Servicio de Oncologia, Barcelona, Spain
πͺπΈHospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain
Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors
- First Posted Date
- 2011-06-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01363024
Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2011-05-30
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT01362374
- Locations
- π«π·
Institut Gustave Roussy; Departement Oncologie Medicale, Villejuif, France
πΊπΈFlorida Cancer Specialists - Sarasota, Sarasota, Florida, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States